Mylan In Australia

Mylan entered the Australian market in 2007, following its acquisition of Alphapharm, a company supplying generic medicines in Australia since 1982. Together, we have built on this legacy in providing patients greater access to affordable medicine in Australia and around the world.

In Australia, Mylan is the leading supplier of medicines by volume to the Pharmaceutical Benefits Scheme (PBS)*. One in six PBS-subsidised medicines dispensed is a Mylan product*. This contributes to the sustainability of the PBS by providing timely access for patients to quality, safe, efficacious and affordable medicines.

Since pioneering generic substitution of medicines in Australia, Mylan has transformed into one of Australia’s leading healthcare companies. Global acquisitions of Abbott’s non-U.S. developed markets speciality and branded generics business and Meda have enabled Mylan to evolve our patient and pharmacy offering. Along with our generics business, we offer a range of innovative brands and over the counter medicines, to offer Australian patients a range of choice for their medical needs.

Mylan also manufactures medicines here in Australia. In fact, we have one of Australia’s largest medicine manufacturing sites, based out of Carole Park, Queensland. We are able to produce over 3 billion doses of oral solid dose medicine for the Australian and export markets. You can find Mylan’s Australian-made medicine in almost 50 countries around the world.

*Expenditure and prescriptions 12 months to 30 June 2017. Pharmaceutical Benefits Scheme. Available at: Pharmaceutical Benefits Scheme website

Mylan in Australia at a Glance

  • We are the leading supplier of medicines by volume to the PBS.*

  • About 1 in 6 prescriptions dispensed is a Mylan medicine*

  • Alphapharm has supplied generic and branded medicines in Australia for over 30 years

  • Mylan acquired Alphapharm in 2007

  • We manufactured about 3 billion doses at Carole Park in 2016.

  • Export to approximately 50 countries

  • In 2015, Mylan further expands our branded products portfolio via acquisition of Abbott's Non-U.S. Developed Markets Specialty and Branded Generics business.
Last Updated  30/10/2018